Sugi Predict

Sugi Predict / Compounds / SCHEMBL2422073

SCHEMBL2422073

SCHEMBL2422073

O=C(Cl)c1ccc(OC(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.61
▸ GFER P55789 1/20 0.61
▸ ADAM17 P78536 1/20 0.61
▸ ATM Q13315 1/20 0.53
▸ ALDH1A1 P00352 6/20 0.47
▸ HTT P42858 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ TSHR P16473 1/20 0.45
▸ MDM2 Q00987 1/20 0.45
▸ HDAC3 O15379 1/20 0.45
▸ HDAC4 P56524 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC7 Q8WUI4 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ HDAC10 Q969S8 1/20 0.45
▸ HDAC11 Q96DB2 1/20 0.45
▸ HDAC8 Q9BY41 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ HDAC9 Q9UKV0 1/20 0.45
▸ HDAC5 Q9UQL6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7441523 0.85 ALOX15 (0.47) ALOX15GFERADAM17ATMALDH1A1
SCHEMBL9169493 0.84 ALOX15 (0.44) ALOX15GFERADAM17ATMALDH1A1
SCHEMBL7042503 0.83 ALOX15 (0.66) ALOX15GFERADAM17ATMALDH1A1
SCHEMBL2791684 0.83 ALOX15 (0.66) ALOX15GFERADAM17ATMALDH1A1
SCHEMBL24400226 0.81 ALOX15 (0.63) ALOX15GFERADAM17ATMALDH1A1
SCHEMBL1018588 0.81 KMT2A (0.64) ALOX15GFERADAM17ATMALDH1A1
SCHEMBL28208867 0.81 ALOX15 (0.63) ALOX15GFERADAM17ATMALDH1A1
SCHEMBL1906677 0.79 ALOX15 (0.61) ALOX15GFERADAM17ATMALDH1A1
SCHEMBL2762402 0.79 PARP10 (0.66) ALOX15GFERADAM17ATMALDH1A1
Hydrochloric Acid SCHEMBL9015381 0.79 KMT2A (0.62) ALOX15GFERADAM17ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577206-B2 Pyrazolone formyl peptide 2 receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2026-03-17 — — US disclosed
CN-111936471-B Non-fused thiophene derivatives and uses thereof 埃尼奥制药公司 2024-10-29 — — CN disclosed
EP-4178949-B9 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2024-09-04 — — EP disclosed
EP-4178949-B1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2024-06-19 — — EP disclosed
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 — — US disclosed
US-11767316-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-09-26 — — US disclosed
US-20230250063-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-08-10 — — US disclosed
US-20230250063-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-08-10 — — US disclosed
US-20230250063-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-08-10 — — US disclosed
EP-4178949-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS Bristol-Myers Squibb Company (US) 2023-05-17 — — EP disclosed
EP-0659737-B1 Catecholamine surrogates useful as beta 3 agonists BRISTOL MYERS SQUIBB CO (US) 2003-03-26 — — EP disclosed
US-5776983-A ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-07-07 — — US disclosed
US-5723489-A ADRENERGIC BLOCKING AGENTS OR STIMULANTS FOR GASTROINTESTINAL DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-03-03 — — US disclosed
EP-0714883-A1 Aryloxypropanolamine beta 3 adrenergic agonists BRISTOL-MYERS SQUIBB COMPANY (US) 1996-06-05 — — EP disclosed
CN-1109050-A Catecholamine surrogates useful as beta3 agonists BRISTOL MYERS SQUIBB CO (US) 1995-09-27 — — CN disclosed
EP-0659737-A2 Catecholamine surrogates useful as B3 agonists BRISTOL-MYERS SQUIBB COMPANY (US) 1995-06-28 — — EP disclosed
US-4673740-A Preparation of substituted 2-phenyl-4H-3,1-benzoxazin-4-ones BASF AKTIENGESELLSCHAFT (DE) 1987-06-16 — — US disclosed
EP-0199276-A2 Process for preparaing substituted 2-phenyl-4H-3,1-benzoxazin-4-ones BASF Aktiengesellschaft (DE) 1986-10-29 — — EP disclosed
US-4009208-A N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) STERLING DRUG INC. (US) 1977-02-22 — — US disclosed
US-3960945-A 4-[-(Alkoxy or polyhaloalkoxy)-benzamido]cyclohexanones STERLING DRUG INC. (US) 1976-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577206-B2 Pyrazolone formyl peptide 2 receptor agonists FPR2, FPR1, FPR3 ALOX15 631/4885GFER 1974/4885ADAM17 3398/4885
US-11767316-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH ALOX15 1943/4885GFER 993/4885ADAM17 4206/4885
US-20230250063-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS FPR2, FPR1, FPR3 ALOX15 416/4885GFER 2240/4885ADAM17 1885/4885
US-11840527-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH ALOX15 1943/4885GFER 993/4885ADAM17 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.